Patients with GPP were more likely to receive topical steroids (multiple), systemic steroids, tumor necrosis factor inhibitors, and interleukin inhibitors than those with plaque psoriasis (Figure 4). The gene discussed is TNF; the disease is psoriasis vulgaris.